G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of novel small molecule therapeutics for the treatment of patients with cancer. The Company’s product pipeline currently includes three clinical-stage product candidates with the potential to significantly improve the treatment of patients with cancer. Trilaciclib and lerociclib are based on the extensive understanding of cyclin-dependent kinases 4 and 6, or CDK4/6, a pair of proteins that play an important role in the growth and proliferation of certain human cells. G1T48 is a potential first-in-class oral SERD. Trilaciclib and lerociclib have broad therapeutic potential in many forms of cancer and multiple combination regimens. G1T48, as a monotherapy or in combination with CDK4/6 inhibitors such as lerociclib, may have the potential to provide a new treatment option for women with ER+ breast cancer.